FI66360C - Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2-fenyl-1h-perimidiner - Google Patents
Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2-fenyl-1h-perimidiner Download PDFInfo
- Publication number
- FI66360C FI66360C FI783808A FI783808A FI66360C FI 66360 C FI66360 C FI 66360C FI 783808 A FI783808 A FI 783808A FI 783808 A FI783808 A FI 783808A FI 66360 C FI66360 C FI 66360C
- Authority
- FI
- Finland
- Prior art keywords
- perimidine
- preparation
- formula
- diaminonaphthalene
- reacted
- Prior art date
Links
- KXLJLJJNISGKPN-UHFFFAOYSA-N 2-phenyl-1h-perimidine Chemical compound C1=CC=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 KXLJLJJNISGKPN-UHFFFAOYSA-N 0.000 title claims description 9
- 238000010276 construction Methods 0.000 title 1
- 239000003337 fertilizer Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- 230000003409 anti-rejection Effects 0.000 claims description 9
- YFOOEYJGMMJJLS-UHFFFAOYSA-N 1,8-diaminonaphthalene Chemical compound C1=CC(N)=C2C(N)=CC=CC2=C1 YFOOEYJGMMJJLS-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Chemical group 0.000 claims description 5
- -1 p-trifluoromethylphenyl Chemical group 0.000 claims description 5
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 claims description 3
- WKZXFTXRGGTUAF-UHFFFAOYSA-N 4-(1,1,2,2,2-pentafluoroethoxy)benzoyl chloride Chemical compound FC(F)(F)C(F)(F)OC1=CC=C(C(Cl)=O)C=C1 WKZXFTXRGGTUAF-UHFFFAOYSA-N 0.000 claims description 3
- UKJWAZZCGZQPTA-UHFFFAOYSA-N 4-(trifluoromethoxy)benzoyl fluoride Chemical compound FC(=O)C1=CC=C(OC(F)(F)F)C=C1 UKJWAZZCGZQPTA-UHFFFAOYSA-N 0.000 claims description 3
- OXLNFFBYPUFBCX-UHFFFAOYSA-N 4-(trifluoromethyl)benzenecarbothioyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=S)C=C1 OXLNFFBYPUFBCX-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 claims description 2
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- UNMBZKGPHRZGRO-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-1h-perimidine Chemical compound FC(F)(F)C1=CC=CC(C=2NC=3C=CC=C4C=CC=C(C=34)N=2)=C1 UNMBZKGPHRZGRO-UHFFFAOYSA-N 0.000 claims 1
- YGWDJCZVFSIHTI-UHFFFAOYSA-N 2-[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1h-perimidine Chemical compound C1=CC(OC(F)(F)C(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 YGWDJCZVFSIHTI-UHFFFAOYSA-N 0.000 claims 1
- HAWBALXIAKBCST-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]-1h-perimidine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 HAWBALXIAKBCST-UHFFFAOYSA-N 0.000 claims 1
- FIIIZHDAZFALEJ-UHFFFAOYSA-N 2-[4-(trifluoromethylsulfanyl)phenyl]-1h-perimidine Chemical compound C1=CC(SC(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 FIIIZHDAZFALEJ-UHFFFAOYSA-N 0.000 claims 1
- 241000277284 Salvelinus fontinalis Species 0.000 claims 1
- 150000003855 acyl compounds Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003990 capacitor Substances 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- NTNWKDHZTDQSST-UHFFFAOYSA-N naphthalene-1,2-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CC=C21 NTNWKDHZTDQSST-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VPEJMJCUOXHVRM-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-1h-perimidine;hydrochloride Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 VPEJMJCUOXHVRM-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000005052 perimidines Chemical class 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KZJZPUCKWRQKEE-UHFFFAOYSA-N 1h-perimidine;hydrochloride Chemical compound Cl.N1C=NC2=CC=CC3=CC=CC1=C32 KZJZPUCKWRQKEE-UHFFFAOYSA-N 0.000 description 2
- VQHBDGIIHYIOAB-UHFFFAOYSA-N 2-(4-methylphenyl)-1h-perimidine Chemical compound C1=CC(C)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 VQHBDGIIHYIOAB-UHFFFAOYSA-N 0.000 description 2
- JLLGZSXMMPKRFI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-1h-perimidine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2NC=3C=CC=C4C=CC=C(C=34)N=2)=C1 JLLGZSXMMPKRFI-UHFFFAOYSA-N 0.000 description 2
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- WNDACGMBVBWZGO-UHFFFAOYSA-N (4-bromophenyl) 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1=CC=C(Br)C=C1 WNDACGMBVBWZGO-UHFFFAOYSA-N 0.000 description 1
- JHBWYQRKOUBPCA-UHFFFAOYSA-N 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)NC1=CC=CC=C1 JHBWYQRKOUBPCA-UHFFFAOYSA-N 0.000 description 1
- BGNSROFPLXZBJD-UHFFFAOYSA-N 1-bromo-4-(1,1,2,2,2-pentafluoroethoxy)benzene Chemical compound FC(F)(F)C(F)(F)OC1=CC=C(Br)C=C1 BGNSROFPLXZBJD-UHFFFAOYSA-N 0.000 description 1
- KUVIAYZHSWMDSV-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-1h-perimidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 KUVIAYZHSWMDSV-UHFFFAOYSA-N 0.000 description 1
- PNPZNBSCKVIFFJ-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2,3-dihydro-1h-perimidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C(N1)NC2=C3C1=CC=CC3=CC=C2 PNPZNBSCKVIFFJ-UHFFFAOYSA-N 0.000 description 1
- YYDAUEXKAFVRJS-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-1h-perimidine Chemical class C1=C(OC)C(OC)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 YYDAUEXKAFVRJS-UHFFFAOYSA-N 0.000 description 1
- LRYDENSZNBLAKU-UHFFFAOYSA-N 2-(3-bromophenyl)-1h-perimidine Chemical compound BrC1=CC=CC(C=2NC=3C=CC=C4C=CC=C(C=34)N=2)=C1 LRYDENSZNBLAKU-UHFFFAOYSA-N 0.000 description 1
- DJDYQGIUDXFEBG-UHFFFAOYSA-N 2-(4-bromophenyl)-1h-perimidine Chemical compound C1=CC(Br)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 DJDYQGIUDXFEBG-UHFFFAOYSA-N 0.000 description 1
- YSRRRCGJBGQBDM-UHFFFAOYSA-N 2-(4-bromophenyl)-2,3-dihydro-1h-perimidine Chemical compound C1=CC(Br)=CC=C1C(N1)NC2=C3C1=CC=CC3=CC=C2 YSRRRCGJBGQBDM-UHFFFAOYSA-N 0.000 description 1
- PYNMVASVFWXKSK-UHFFFAOYSA-N 2-(4-chlorophenyl)-1h-perimidine Chemical compound C1=CC(Cl)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 PYNMVASVFWXKSK-UHFFFAOYSA-N 0.000 description 1
- KYZVDBPJDCCYMN-UHFFFAOYSA-N 2-(4-chlorophenyl)-2,3-dihydro-1h-perimidine Chemical compound C1=CC(Cl)=CC=C1C(N1)NC2=C3C1=CC=CC3=CC=C2 KYZVDBPJDCCYMN-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DFLDLLFXZDCVTA-UHFFFAOYSA-N 2-[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-1h-perimidine;hydrochloride Chemical compound Cl.C1=CC(OC(F)(F)C(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 DFLDLLFXZDCVTA-UHFFFAOYSA-N 0.000 description 1
- GWNJOICTHJUGJU-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]-1h-perimidine;hydrofluoride Chemical compound F.C1=CC(OC(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 GWNJOICTHJUGJU-UHFFFAOYSA-N 0.000 description 1
- QXTPKJORYIYHLG-UHFFFAOYSA-N 2-[4-(trifluoromethylsulfanyl)phenyl]-1h-perimidine;hydrochloride Chemical compound Cl.C1=CC(SC(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 QXTPKJORYIYHLG-UHFFFAOYSA-N 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- PORLFHXSSVTTPD-UHFFFAOYSA-N 4-(trichloromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(Cl)(Cl)Cl)C=C1 PORLFHXSSVTTPD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- GHICCUXQJBDNRN-UHFFFAOYSA-M 4-iodobenzoate Chemical compound [O-]C(=O)C1=CC=C(I)C=C1 GHICCUXQJBDNRN-UHFFFAOYSA-M 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CREHACCKBXNWPL-UHFFFAOYSA-N Cl.FC(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)(F)F Chemical compound Cl.FC(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)(F)F CREHACCKBXNWPL-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CWHZOJVAPFMFOG-UHFFFAOYSA-N NC1=CC=CC2=CC=CC(=C12)N.Cl.FC(C(F)(F)F)(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)F Chemical compound NC1=CC=CC2=CC=CC(=C12)N.Cl.FC(C(F)(F)F)(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)F CWHZOJVAPFMFOG-UHFFFAOYSA-N 0.000 description 1
- PVUIPSRHQDWJAH-UHFFFAOYSA-N NC1=CC=CC2=CC=CC(=C12)N.F.FC(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)(F)F Chemical compound NC1=CC=CC2=CC=CC(=C12)N.F.FC(OC1=CC=C(C=C1)C=1NC=2C=CC=C3C=CC=C(N1)C23)(F)F PVUIPSRHQDWJAH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031068 Orchitis mumps Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MABCMWISTJAYLR-UHFFFAOYSA-N naphthalene-1,8-diamine 2-[3-(trifluoromethyl)phenyl]-1H-perimidine hydrochloride Chemical compound NC1=CC=CC2=CC=CC(=C12)N.Cl.FC(C=1C=C(C=CC1)C=1NC=2C=CC=C3C=CC=C(N1)C23)(F)F MABCMWISTJAYLR-UHFFFAOYSA-N 0.000 description 1
- IRGAPAYCZKPVFF-UHFFFAOYSA-N naphthalene-1,8-diamine;2-[4-(trifluoromethylsulfanyl)phenyl]-1h-perimidine;hydrochloride Chemical compound Cl.C1=CC(N)=C2C(N)=CC=CC2=C1.C1=CC(SC(F)(F)F)=CC=C1C(N1)=NC2=CC=CC3=CC=CC1=C23 IRGAPAYCZKPVFF-UHFFFAOYSA-N 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI832540A FI66361C (fi) | 1977-12-19 | 1983-07-12 | Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2,3-dihydro-2-fenyl-1h-perimidiner |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86173277A | 1977-12-19 | 1977-12-19 | |
| US86173277 | 1977-12-19 | ||
| US94443478 | 1978-09-21 | ||
| US05/944,434 US4224326A (en) | 1978-09-21 | 1978-09-21 | Immunosuppressive agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI783808A7 FI783808A7 (fi) | 1979-06-20 |
| FI66360B FI66360B (fi) | 1984-06-29 |
| FI66360C true FI66360C (fi) | 1984-10-10 |
Family
ID=27127642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI783808A FI66360C (fi) | 1977-12-19 | 1978-12-12 | Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2-fenyl-1h-perimidiner |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0002906B1 (ro) |
| JP (1) | JPS5488279A (ro) |
| AR (1) | AR218350A1 (ro) |
| AT (1) | AT367045B (ro) |
| AU (1) | AU522740B2 (ro) |
| CA (1) | CA1079281A (ro) |
| CH (1) | CH636863A5 (ro) |
| CS (1) | CS207699B2 (ro) |
| DD (1) | DD139849A5 (ro) |
| DE (1) | DE2861747D1 (ro) |
| DK (1) | DK144699C (ro) |
| ES (1) | ES476153A1 (ro) |
| FI (1) | FI66360C (ro) |
| FR (1) | FR2411834A1 (ro) |
| GB (1) | GB2010246B (ro) |
| GR (1) | GR70262B (ro) |
| HU (1) | HU178528B (ro) |
| IE (1) | IE47619B1 (ro) |
| IL (1) | IL56211A (ro) |
| IT (1) | IT1101673B (ro) |
| LU (1) | LU80662A1 (ro) |
| MX (1) | MX5563E (ro) |
| NZ (1) | NZ189150A (ro) |
| PL (1) | PL113258B1 (ro) |
| PT (1) | PT68903A (ro) |
| RO (1) | RO72250A (ro) |
| SU (1) | SU984409A3 (ro) |
| YU (1) | YU297678A (ro) |
| ZA (1) | ZA787054B (ro) |
-
1978
- 1978-12-12 AR AR274760A patent/AR218350A1/es active
- 1978-12-12 NZ NZ189150A patent/NZ189150A/xx unknown
- 1978-12-12 AU AU42431/78A patent/AU522740B2/en not_active Expired
- 1978-12-12 JP JP15407178A patent/JPS5488279A/ja active Pending
- 1978-12-12 PT PT68903A patent/PT68903A/pt unknown
- 1978-12-12 FI FI783808A patent/FI66360C/fi not_active IP Right Cessation
- 1978-12-13 FR FR7835084A patent/FR2411834A1/fr active Granted
- 1978-12-13 GB GB7848213A patent/GB2010246B/en not_active Expired
- 1978-12-13 CA CA317,876A patent/CA1079281A/en not_active Expired
- 1978-12-13 DE DE7878300799T patent/DE2861747D1/de not_active Expired
- 1978-12-13 EP EP78300799A patent/EP0002906B1/en not_active Expired
- 1978-12-14 MX MX787596U patent/MX5563E/es unknown
- 1978-12-14 IL IL56211A patent/IL56211A/xx unknown
- 1978-12-15 IT IT30926/78A patent/IT1101673B/it active
- 1978-12-15 LU LU80662A patent/LU80662A1/xx unknown
- 1978-12-18 PL PL1978211890A patent/PL113258B1/pl unknown
- 1978-12-18 SU SU782697059A patent/SU984409A3/ru active
- 1978-12-18 GR GR57920A patent/GR70262B/el unknown
- 1978-12-18 DK DK567578A patent/DK144699C/da not_active IP Right Cessation
- 1978-12-18 ZA ZA787054A patent/ZA787054B/xx unknown
- 1978-12-18 IE IE2487/78A patent/IE47619B1/en unknown
- 1978-12-18 YU YU02976/78A patent/YU297678A/xx unknown
- 1978-12-18 HU HU78EI827A patent/HU178528B/hu unknown
- 1978-12-18 AT AT0904278A patent/AT367045B/de not_active IP Right Cessation
- 1978-12-18 RO RO7895966A patent/RO72250A/ro unknown
- 1978-12-18 CH CH1284178A patent/CH636863A5/fr not_active IP Right Cessation
- 1978-12-19 ES ES476153A patent/ES476153A1/es not_active Expired
- 1978-12-19 CS CS788575A patent/CS207699B2/cs unknown
- 1978-12-19 DD DD78209925A patent/DD139849A5/de unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU843746A3 (ru) | Способ получени аминотиазоловили иХ КиСлОТНО-АддиТиВНыХ СОлЕй | |
| CA1199024A (en) | Immunoregulatory diketopiperazine compounds | |
| US6444706B2 (en) | Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | |
| FI66360C (fi) | Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2-fenyl-1h-perimidiner | |
| US4224326A (en) | Immunosuppressive agents | |
| CA1061788A (en) | 5-m-tolyloxyuracil, anti-ulcer agent | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| US4294964A (en) | 2-Aryl-1H-perimidines | |
| US4064127A (en) | Trifluoromethyl dibenzo[a,c]phenazines as immune regulants | |
| US3297699A (en) | 5-nitrothiazolyl-dioxo-diazacycloalkanes | |
| FI66361C (fi) | Analogifoerfarande foer framstaellning av saosom avstoetning motstaoende aemnen anvaendbara 2,3-dihydro-2-fenyl-1h-perimidiner | |
| US3860718A (en) | IMIDAZO (2,1-b) THIAZOLE AND THIAZOLO (3,2-a) BENZIMIDAZOLE QUATERNARY SALTS HYPOGLYCEMIC AGENTS | |
| US3222395A (en) | Maleamic ackd derivatives | |
| KR900000968B1 (ko) | 1,2-디티올-3-티온 유도체, 이의 제조방법 및 조성물 | |
| KR820000865B1 (ko) | 2-아릴-1h-페리미딘 유도체의 제조방법 | |
| CS207700B2 (cs) | Způsob výroby nových 2-aryl-1H-perimidinových sloučenin | |
| DK144911B (da) | Analogifremgangsmaade til fremstilling af 2,3-dihydro-2-phenyl- 1h-perimidiner eller salte heraf | |
| FI83081B (fi) | Foerfarande foer framstaellning av en ny bronkodilatoriskt verkande 2,3-tetrametylen-4-oxo-4,6,7,8,9,10- hexahydroazepino/1,2-a/pyrimidinhydroklorid. | |
| DE3514351A1 (de) | Neue substituierte 2-(n-alkinyl-n-phenyl)amino)-imidazolinderivate, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung | |
| CA2073281A1 (en) | Isatineoxime derivatives, their preparation and use | |
| CA1150268A (en) | Decaprenylamine derivatives | |
| US3928596A (en) | Pharmaceutical compositions of 5,6-dialkoxy-2-aminobenzimidazoles and method for treating hypertension | |
| NZ221939A (en) | 1-aryloxy-dihydrobenzothiadiazinylalkylamino-alkanes, pharmaceuticals and their preparations | |
| EP0172917A1 (en) | Agents for treating immunodeficiency, method for treating them, and use thereof | |
| JPS59167515A (ja) | 免疫機能増強剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HF | Priority information amended | ||
| FD | Application lapsed | ||
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: ELI LILLY AND COMPANY |